John Teerlink
Chairman of Advisory
Dr. Teerlink leads the team of advisors and colleagues and has been an active member of the Heart Failure Society of America, serving on multiple committees. John completed a four-year term as a permanent member of the FDA Cardiovascular and Renal Drugs Advisory Committee, and currently serves as an ad hoc member of multiple other FDA advisory committees. He is a member of the joint FDA/Duke University initiative to develop standardized definitions for cardiovascular endpoints. John is actively involved in the design and execution of many acute and chronic heart failure clinical trials, serving on endpoint, data safety monitoring, and steering committees for numerous international studies investigating a variety of new therapies, including tezosentan (RITZ program, VERITAS), levosimendan (REVIVE), nesiritide (ASCEND-HF), serelaxin (Pre-RELAX-AHF, RELAX-AHF), rolofylline (PROTECT), omecamtiv mecarbil (CY1111, CY1121, ATOMIC-AHF, COSMIC-HF), warfarin/ aspirin (WARCEF), and LCZ696 (PARADIGM-HF). John is Director of the HF Program/Clinical Echocardiography Lab at the San Francisco Veterans Medical Center. He graduated from Swarthmore College (Honors) and earned his MD from Harvard Medical School then completed a residency at UCSF. He did basic science training as a post-doctoral fellow at Hoffman-LaRoche. John completed a cardiovascular medicine fellowship and a Howard Hughes post-doctoral research fellowship at UCSF, subsequently joining the faculty, where he currently is a Professor of Medicine. He was an Associate Editor for the Journal of Cardiac Failure, is currently the Guest Editor-in-Chief for JACC: Heart Failure, and is a clinical scholar presenting many lectures and publications, including a chapter on Acute Heart Failure in Braunwald’s Heart Disease textbook. He was recently profiled in The Lancet as an internationally recognized leader in heart failure.